This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fefer, A. Search for Related Content PubMed PubMed Citation Articles by Fefer, A.

Immunotherapy and Chemotherapy of Moloney Sarcoma Virus-induced Tumors in Mice¹

Division of Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98105

Regression of autochthonous (primary) murine sarcoma virus (Moloney) (MSV)-induced tumors was first detectable in 13% of BALB/c mice inoculated with MSV at 3 weeks of age and increased in incidence thereafter. This correlated with the ability to resist transplanted BALB/c Moloney sarcoma (MS) cells. Treatment of young BALB/c mice bearing palpable primary tumors with spleen cells or with serum from adult BALB/c or CDF (BALB/c x DBA)F₁ mice whose autochthonous tumors had regressed resulted in complete tumor regression in 34–40% of the hosts. Such immune cells, in conjunction with cyclophosphamide (CY), were also effective in eradicating palpable transplanted tumors.

Primary tumors were moderately sensitive to CY. However, CY given to young mice bearing primary tumors transiently inhibited tumor growth and doubled host survival time, whereas CY given to adult tumor-bearing mice decreased tumor growth but also depressed immunologic reactivity, thereby preventing tumor regression. This illustrates a potential danger in treating a host already responding against his tumor with a chemotherapeutic agent possessing potent immunosuppressive activity. Specific immunotherapy prevented the deleterious effect of CY. Most adult BALB/c mice bearing palpable primary tumors and inoculated with CY were cured by spleen cells or by serum from BALB/c, CDF, or (BALB/c x C57BL/6)F₁ mice hyperimmunized by MSV, but not by cells from unimmunized mice or by anti-BALB/c serum. The results show that established primary MSV-induced tumors can be cured by lymphoid cells or serum from syngeneic or allogeneic donors specifically sensitized to MSV-induced tumor antigens.

¹ Supported by Grant No. CA 10777 from the National Cancer Institute, NIH.

Received 2/ 3/69. Accepted 4/21/69.

This article has been cited by other articles:

				C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al. Toll-like Receptors in Tumor Immunotherapy Clin. Cancer Res., September 15, 2007; 13(18): 5280 - 5289. [Abstract] [Full Text] [PDF]

				O. Stutman Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice Science, February 8, 1974; 183(4124): 534 - 536. [Abstract] [PDF]

				C. C Congdon Bone Marrow Transplantation Science, March 19, 1971; 171(3976): 1116 - 1124. [Abstract] [PDF]